Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

78.72 -0.05 (-0.06%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,220,993
Open 79.11
Bid (Size) 78.30 (3)
Ask (Size) 78.52 (6)
Prev. Close 78.77
Today's Range 78.26 - 79.20
52wk Range 62.07 - 87.86
Shares Outstanding 1,253,809,440
Dividend Yield 3.81%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Peering Into Gilead Sciences's Recent Short Interest
Via Benzinga
Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire

Performance

YTD
-5.43%
-5.43%
1 Month
+6.38%
+6.38%
3 Month
+21.67%
+21.67%
6 Month
+4.79%
+4.79%
1 Year
+6.46%
+6.46%

More News

Read More
Unveiling 10 Analyst Insights On Gilead Sciences
Via Benzinga
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
Via Benzinga
Gilead Sciences Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Via Benzinga
Peering Into Gilead Sciences's Recent Short Interest
Via Benzinga
Biotech And Life Science Sector Update Summer Of 2024
Via Talk Markets
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
Via Investor's Business Daily
Exposures Product Safety
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Biotech Bull Market: 3 Ways To Play It
Via Talk Markets
Topics Economy
Exposures Interest Rates
Gilead's Ongoing Battle Against Counterfeit HIV Medications Persists With New Lawsuit, Seizes $750K In Fake Drugs
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Expert Outlook: Gilead Sciences Through The Eyes Of 8 Analysts
Via Benzinga
Gilead Eyes A Breakout After Second-Quarter Sales, Earnings Beat
Via Investor's Business Daily
FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal
Via Benzinga
Exposures Product Safety
Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
From Gilead Sciences, Inc.
Via Business Wire
7 Defensive Stocks to Buy as Investors Seek Shelter
Via InvestorPlace
3 Stocks Retirees Should Absolutely Love
Via The Motley Fool
Analysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels
Via Benzinga
Wall Street Momentum Stalls After Thursday's Rally, Palantir Jumps To 3-Year Highs, Bonds Rally: What's Driving Markets Friday?
Via Benzinga
Gilead Sciences (GILD) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Gilead Sciences Announces Second Quarter 2024 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Wall Street Rallies As Economic Concerns Recede, Tech Flexes Its Muscles, Semiconductors Soar: What's Driving Markets Thursday?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.